Breaking News, Collaborations & Alliances

Evotec, Janssen in Depression Agreement

Janssen to develop NMDA antagonist treatments

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG has entered into a license agreement with Janssen Pharmaceuticals for its NR2B subtype selective NMDA-antagonist portfolio for development to treat diseases related to depression.   Janssen has an exclusive, worldwide license to a series of small molecule drug candidates to further develop the compounds and market the resulting products. Janssen’s affiliate, Janssen R&D, LLC, will conduct the clinical development work.   Evotec will receive $2 million upfront and an additional $6 m...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters